SUNNYVALE, Calif., Jan. 7 /PRNewswire/ -- Biocircuits Corporation
(Nasdaq: BIOC or the "Company") today announced that, based on currently
available information, it expects to report product sales of approximately
$200,000 for fourth quarter 1996.  The Company reported product sales of
$50,000 for third quarter 1996.
    Biocircuits anticipates the net loss for the fourth quarter 1996 to be in
the range of $0.47 per share to $0.52 per share.  In the third quarter 1996,
the Company's net loss was $0.60 per share.  The Company expects to report
fourth quarter results on January 22.
    "We are pleased with the rate of revenue growth from third quarter 1996 to
fourth quarter 1996.  We believe it is the first confirmation that launching
the TSH test, which was done in late December, will lead to increased
revenues," said John Kaiser, President and Chief Executive Officer of
Biocircuits.
    In March 1996, Biocircuits began selling its IOS(R) immunodiagnostic
system and initial tests in the United States.  The IOS system incorporates a
low-cost, compact instrument and patented, disposable test cartridges.  It is
the first cost-effective, easy-to-use immunodiagnostic system available for
use in physicians' offices and other point-of-care sites.  The initial tests
used in the IOS system were a combined T4 and T Uptake assay to assess thyroid
function.  In September 1996, the Company announced FDA clearance to market a
qualitative serum pregnancy assay, a test designed to allow physicians to
perform this common pregnancy test in their offices during the patient visit
in order to provide more immediate pre-natal care.  In December 1996, the
Company announced FDA clearance to market a Quantitative hCG assay, a test to
track the progress of early pregnancies.  Also in December 1996, the Company
launched its TSH assay on the second generation cartridge.  The second
generation cartridge will be required for the market launch of all new assays.
In addition, existing assays will be converted to the new cartridge in the
near future.
    Biocircuits is currently developing three additional assays for its IOS
system: a PSA test for the management of prostate cancer patients, a Digoxin
test for monitoring the therapeutic usage of this drug in the treatment of
heart disease and a Free T4 test for diagnosing true clinical thyroid status.
The Company currently plans to continue developing additional immunodiagnostic
assays that are commonly requested by office-based physicians.
    With its IOS system, Biocircuits is targeting the approximately 41,000
small- to medium-sized physician office practices and free-standing alternate
site laboratories which are licensed under CLIA for high or moderate
complexity testing.  Most of these sites do not currently have an
immunodiagnostic testing capability.  The IOS system is approved for
moderately complex testing.
    Biocircuits Corporation, based in Sunnyvale, California, is focused on the
development and commercialization of innovative and cost-effective
immunodiagnostic products.
    Actual results may differ materially from the above forward-looking
statements due to a number of important factors, and will be dependent upon
the Company's ability, directly or through third parties, to successfully
manufacture and market its existing and proposed products, as well as the
timely development and regulatory approval of additional products.  These
factors are more fully discussed in the Company's most recent reports on Forms
10-K and 10-Q and the Company's Resale Registration Statement No. 333-13673.

Link to this page: